A group of blood pressure medications may hold the key to better outcomes for those with COVID-19, marking a significant breakthrough in the treatment of the virus.
An exciting new study, involving researchers from across Australia and India, will investigate whether existing blood pressure medications can reduce the risk of severe disease as well as the duration of severe symptoms.
Researchers from Royal North Shore Hospital will support a team led by Associate Professor Meg Jardine from The George Institute for Global Health.
Professor Carol Pollock, who will lead the trial at RNSH, said the CLARITY study will involve up to 600 patients over the next year.
"The trial will investigate whether a class of drugs called angiotensin receptor blockers can improve outcomes for COVID-19 patients, by interrupting the virus’ entry into the body’s cells," she said.
"We’ll also be looking at whether these medications can protect patients against lung injury from COVID-19, a common outcome for those with severe symptoms.